Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.

Garg, Manoj; Kanojia, Deepika; Mayakonda, Anand; Said, Jonathan W; Doan, Ngan B; Chien, Wenwen; Ganesan, Trivadi S; Chuang, Linda Shyue Huey; Venkatachalam, Nachiyappan; Baloglu, Erkan; Shacham, Sharon; Kauffman, Michael; Koeffler, H Phillip

Garg, Manoj; Kanojia, Deepika; Mayakonda, Anand; Said, Jonathan W; Doan, Ngan B; Chien, Wenwen; Ganesan, Trivadi S; Chuang, Linda Shyue Huey; Venkatachalam, Nachiyappan; Baloglu, Erkan; Shacham, Sharon; Kauffman, Michael; Koeffler, H Phillip.

Affiliation

Garg M; Cancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore.
Kanojia D; Department of Medical Oncology and Clinical Research, Cancer Institute (WIA), Adyar Chennai, India.
Mayakonda A; Cancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore.
Said JW; Cancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore.
Doan NB; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, Los Angeles, CA, USA.
Chien W; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, Los Angeles, CA, USA.
Ganesan TS; Cancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore.
Chuang LS; Department of Medical Oncology and Clinical Research, Cancer Institute (WIA), Adyar Chennai, India.
Venkatachalam N; Cancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore.
Baloglu E; Cancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore.
Shacham S; Karyopharm Therapeutics Inc, Newton, MA, USA.
Kauffman M; Karyopharm Therapeutics Inc, Newton, MA, USA.
Koeffler HP; Karyopharm Therapeutics Inc, Newton, MA, USA.

Oncotarget ; 8(5): 7521-7532, 2017 Jan 31.

Article in En | MEDLINE | ID: mdl-27893412

Subject(s)

Antineoplastic Agents/pharmacology; Hydrazines/pharmacology; Karyopherins/antagonists & inhibitors; Liposarcoma/drug therapy; Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors; Triazoles/pharmacology; Animals; Apoptosis/drug effects; Aurora Kinase A/metabolism; Aurora Kinase B/metabolism; Cell Cycle Checkpoints/drug effects; Cell Line, Tumor; Cell Proliferation/drug effects; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 5/metabolism; Karyopherins/genetics; Karyopherins/metabolism; Liposarcoma/genetics; Liposarcoma/metabolism; Liposarcoma/pathology; Male; Mice; Proto-Oncogene Proteins c-akt/metabolism; RNA Interference; Receptor, IGF Type 1; Receptors, Cytoplasmic and Nuclear/genetics; Receptors, Cytoplasmic and Nuclear/metabolism; Receptors, Somatomedin/metabolism; Signal Transduction/drug effects; Time Factors; Transfection; Tumor Burden/drug effects; Xenograft Model Antitumor Assays; Exportin 1 Protein

Key words

IGFBP5; cell cycle; selinexor; xenograft

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Triazoles / Receptors, Cytoplasmic and Nuclear / Karyopherins / Hydrazines / Liposarcoma / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: Oncotarget Year: 2017 Type: Article Affiliation country: Singapore

Fulltext

XML

PubMed Links

Search on Google